References
- Ranson M, Wardell S. (2004). Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Phar Ther, 29:95–103.
- Pao W, Miller VA, Kris MG. (2004). ‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (iressa) in non-small cell lung cancer (nsclc). Semin Cancer Biol, 14:33–40.
- Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, al et. (2007). Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors. Int J Pharm, 341:134–42.
- Siegel-Lakhai WS, Beijnen JH, Schellens JHM. (2005). Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (tarceva) and gefitinib (iressa). Oncologist, 10:579–89.
- Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. . Pharm Res, 12:413–20.
- Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, al et. (2005). Single-dose clinical pharmacokinetics studies of gefitinib. Clin Pharmacokinet, 44:1165–77.
- Carrier RL, Miller LA, Ahmed I. (2007). The utility of cyclodextrins for enhancing oral bioavailability. J Control Release, 123:78–99.
- Loftsson T, Brewster ME, Masson M. (2004). Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv, 2:261–75.
- Challa R, Ahuja A, Ali J, Khar RK. (2005). Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech, 6:E329–E357.
- Loftsson T, Duchene D. (2007). Cyclodextrins and their pharmaceutical applications. Int J Pharm, 329:1–11.
- Higuchi T, Connors KA. (1965). Phase solubility techniques. Adv Anal Chem Instrum, 4:117–212.
- Takayama K, Nambu N, Nagai T. (1980). Pharmaceutical interactions in dosage forms and processing. XIX. Dissolution kinetics for coprecipitates of indomethacin with polyvinylpyrrolidone. Chem Pharm Bull, 28:3304–09.
- Khan KA, Rhodes CT. (1972). Effect of compaction pressure on the dissolution efficiency of direct compression systems. Pharm Acta Helv, 47:594–607.
- Liu X, Lin H-S, Thenmozhiyal JC, Chan SY, Ho PC. (2003). Inclusion of acitretin into cyclodextrins: Phase solubility, photostability, and physicochemical characterization. J Pharm. Sci, 92:2449–57.
- Babu RJ, Pandit JK. (2004). Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. Int J Pharm, 27:155–65.
- Loftsson T, Gudmundsdóttir H, Sigurjónsdóttir JF, Sigurdsson HH, Sigfússon SD, Másson M, al et. (2001). Cyclodextrin solubilization of benzodiazepines: Formulation of midazolam nasal spray. Int J Pharm, 212:29–40.
- Veiga F, Teixeira-Dias JJC, Kedzierewicz F, Sousa A, Maincent P. (1996). Inclusion complexation of tolbutamide with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Int J Pharm, 129:63–71.
- Botella SM, Martin MA, Del Castillo B, Menendez JC, Vazquez L, Lerner DA. (1996). Analytical applications of retinoid-cyclodextrin inclusion complexes. 1. Characterization of a retinal-beta-cyclodextrin complex. J Pharm Biomed Anal, 14:909–15.
- Mura P, Adragna E, Rabasco AM, Moyano JR, Perez-Martinez JI, Arias MJ, al et. (1999). Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Drug Dev Ind Pharm, 25:279–87.
- Anzai K, Mizoguchi J, Yanagi T, Hirayama F, Arima H, Uekama K. (2007). Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin. Chem Pharm Bull (Tokyo),, 55:1466–70.
- Chowdary KPR, Srinivas SV. (2006). Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl beta-cyclodextrin. AAPS PharmSciTech,, 7:E1–E6.
- Mura P, Faucci MT, Bettinetti GP. (2001). The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta-cyclodextrin. Eur J Pharm Sci, 13:187–94.